Real, industry-grade financial data — verified financials and ClinicalTrials.gov-checked pipelines — turned into institutional-grade research by human analysts, accelerated by AI. Built for serious European biotech investors, across 350+ US & EU tickers.
Every figure comes from audited, industry-standard sources and verified filings — never invented by a model. AI just helps us surface and structure it faster. Then our community pressure-tests the thesis: vote bull or bear, set a target price, and steer the consensus score on every ticker.
Join the discussionCommunity-validated upside thesis with cited evidence.
Critical risk analysis — the trade you should reconsider.
Build a track record as the community scores how your calls play out over time.
Our sovereign stack pairs a search-grounded frontier model (live citations on every claim) with a second model pinned to verified FMP financials under strict null-handling — so it can't contradict or fabricate the numbers. Our analysts then author the flagship institutional deep-dives by hand in a frontier-model workbench, grounded in that same verified data and cross-checked against ClinicalTrials.gov.
Analysts also cite PubMed, peer-reviewed journals and EMA/MHRA sources directly in institutional deep-dives.
Scores sentiment 0–10 across three independent dimensions — Financial, Technological, and Regulatory — then tracks the divergence vs price.
A continuous headline crawl scored by frontier models. We filter noise to deliver only the high-impact Movers: FDA approvals, M&A, trial readouts.
Automated event extraction parses years of history into a clean chronological timeline for every company — kept current.
Illustrative sample of the scored-news feed.
Bloomberg · 2h ago
PR Newswire · 4h ago
Reuters · 6h ago
Endpts · 8h ago
You drive; the platform does the heavy lifting at every step.
Search 350+ US & EU biotechs and get the full picture in one screen — financials, pipeline, sentiment, catalysts.
Generate a fully-cited frontier-model brief on demand. Our analysts turn the names that matter into 12–15-page institutional deep-dives.
Post your case, call bull or bear with a target price, and watch the consensus score move as the community weighs in.
FDA decisions, trial readouts, insider sells — alerts hit your inbox while the market is still digesting them.
Annual billing is two months free. The Free tier stays free during beta — join the waitlist below.
Top-of-funnel · try the platform
or €190/yr · for serious investors
or €990/yr · prosumers & small funds
annual · funds, IR & data teams
Cancel anytime from your profile. Prices in EUR; VAT is calculated at checkout. The Free tier needs no card.
Create your free account for sovereign-AI biotech research, built for serious European investors.
No card · Cancel anytime · Free during beta
Drop your email and we'll send you an invite when subscriptions open. Free tier. No card. Unsubscribe anytime.